[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Gilead Sciences Inc (GILD)

Gilead Sciences Inc (GILD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 160,994,368
  • Shares Outstanding, K 1,241,570
  • Annual Sales, $ 29,443 M
  • Annual Income, $ 8,510 M
  • EBIT $ 10,370 M
  • EBITDA $ 13,130 M
  • 60-Month Beta 0.31
  • Price/Sales 5.46
  • Price/Cash Flow 12.38
  • Price/Book 6.86

Options Overview Details

View History
  • Implied Volatility 28.74% (-0.42%)
  • Historical Volatility 21.36%
  • IV Percentile 35%
  • IV Rank 32.96%
  • IV High 43.61% on 05/22/25
  • IV Low 21.43% on 12/10/25
  • Expected Move (DTE 3) 3.10 (2.36%)
  • Put/Call Vol Ratio 0.75
  • Today's Volume 2,529
  • Volume Avg (30-Day) 8,663
  • Put/Call OI Ratio 0.57
  • Today's Open Interest 139,785
  • Open Int (30-Day) 167,360
  • Expected Range 128.51 to 134.71

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 32 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-3.04
  • Number of Estimates 8
  • High Estimate $2.14
  • Low Estimate $-7.50
  • Prior Year $2.01
  • Growth Rate Est. (year over year) -251.24%

Price Performance

See More
Period Period Low Period High Performance
1-Month
127.64 +2.86%
on 04/27/26
138.54 -5.23%
on 04/20/26
-6.35 (-4.61%)
since 04/17/26
3-Month
127.64 +2.86%
on 04/27/26
153.26 -14.33%
on 02/20/26
-19.83 (-13.12%)
since 02/19/26
52-Week
104.46 +25.68%
on 06/25/25
157.29 -16.53%
on 02/11/26
+25.13 (+23.67%)
since 05/19/25

Most Recent Stories

More News
Gilead Sciences Leans on HIV Growth as Deals Build Oncology, Inflammation Pipeline

Gilead Sciences (NASDAQ:GILD) Chief Commercial Officer and Head of Corporate Affairs Johanna Mercier said the company is leaning on its HIV business while continuing to build out oncology and inflammation...

GILD : 130.97 (+1.00%)
3 Market-Beating Stocks to Research Further

3 Market-Beating Stocks to Research Further

COR : 267.60 (+2.19%)
GILD : 130.97 (+1.00%)
MRVL : 180.62 (+6.92%)
Gilead Prices $3 Billion of Senior Unsecured Notes

Gilead Sciences, Inc. (Nasdaq: GILD), a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, today announced the pricing of senior unsecured notes...

GILD : 130.97 (+1.00%)
Gilead Sciences’s Q1 Earnings Call: Our Top 5 Analyst Questions

Gilead Sciences’s Q1 Earnings Call: Our Top 5 Analyst Questions

GILD : 130.97 (+1.00%)
Gilead to Present New Data Advancing Care in PBC and Viral Hepatitis at EASL 2026

- Late-Breaking Livdelzi (Seladelpar) Data Expand the Evidence Base in PBC, while Interim Data Show Durable, Consistent Results Across Key Markers - ...

GILD : 130.97 (+1.00%)
GILD Q1 Deep Dive: HIV Growth, Oncology Pipeline, and Margin Management Shape 2026 Outlook

GILD Q1 Deep Dive: HIV Growth, Oncology Pipeline, and Margin Management Shape 2026 Outlook

GILD : 130.97 (+1.00%)
Gilead Sciences Q1 Earnings Call Highlights

Gilead Sciences (NASDAQ:GILD) reported first-quarter 2026 results highlighted by growth in its base business, a higher full-year revenue outlook, and multiple late-stage pipeline and launch milestones...

GILD : 130.97 (+1.00%)
Gilead Sciences’s (NASDAQ:GILD) Q1 CY2026: Beats On Revenue

Gilead Sciences’s (NASDAQ:GILD) Q1 CY2026: Beats On Revenue

GILD : 130.97 (+1.00%)
Gilead: Q1 Earnings Snapshot

Gilead: Q1 Earnings Snapshot

GILD : 130.97 (+1.00%)
Gilead Sciences Announces First Quarter Financial Results

Product Sales Excluding Veklury Increased 8% Year-Over-Year to $6.8 billion Biktarvy Sales Increased 7% Year-Over-Year to $3.4 billion

GILD : 130.97 (+1.00%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Gilead Sciences is a pioneer in developing drugs for the treatment of human immunodeficiency virus, liver diseases, hematology/oncology diseases and inflammation/respiratory diseases. The company has a strong HIV franchise with key HIV/AIDS therapies like tenofovir alafenamide based products - Genvoya,...

See More

Key Turning Points

3rd Resistance Point 132.57
2nd Resistance Point 131.81
1st Resistance Point 130.74
Last Price 130.97
1st Support Level 128.91
2nd Support Level 128.15
3rd Support Level 127.08

See More

52-Week High 157.29
Fibonacci 61.8% 137.11
Last Price 130.97
Fibonacci 50% 130.88
Fibonacci 38.2% 124.64
52-Week Low 104.46

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.